Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions

Front Oncol. 2024 Jan 23:14:1369562. doi: 10.3389/fonc.2024.1369562. eCollection 2024.

Daniele Generali^{1

2}, Rossana Berardi³, Michele Caruso⁴, Marina Cazzaniga^{5

6}, Ornella Garrone⁷, Ida Minchella⁸, Ida Paris⁹, Carmine Pinto¹⁰, Sabino De Placido¹¹

¹ Breast Cancer Unit, Azienda Socio Sanitaria Territoriale di Cremona, Cremona, Italy.
² Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
³ Medical Oncology, Azienda Ospedaliera Universitaria (AOU) delle Marche, University Politecnica delle Marche, Ancona, Italy.
⁴ Humanitas Istituto Clinico Catanese, Breast Centre Humanitas Catania, Catania, Italy.
⁵ School of Medicine and Surgery University of Milano Bicocca, Milan, Italy.
⁶ Phase 1 Research Unit, Azienda Socio Sanitaria Territoriale (ASST) Monza, Monza, Italy.
⁷ Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
⁸ Division of Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
⁹ Department of Woman and Child Health and Public Health, Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricerca e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
¹⁰ Medical Oncology Unit, Comprehensive Cancer Centre, Azienda Unità Sanitaria Locale - Istituto di Ricerca e Cura a Carattere Scientifico (AUSL-IRCCS) di Reggio Emilia, Reggio Emilia, Italy.
¹¹ Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

Abstract

[This corrects the article DOI: 10.3389/fonc.2023.1249160.].

Keywords: aromatase inhibitors; bone loss; breast cancer; cardiotoxicity; drug adherence.